Tumor and stromal chemoresistance
PRINCIPAL INVESTIGATORS
- Maria Lourdes Farre Vallve
CLINICAL RESEARCHERS
- Nuria Ruiz Roig
PREDOCTORAL RESEARCHERS
- Juan Francisco Martín Tejera
- Nerea Albert Colome
- Gemma Garcia Vicien
- Daniel Alvarez Villanueva
- Natalia Molina Valdevira
SCIENTIFIC SUPPORT
- Monica Calaf Sanjuanes
- Maria Bañuls Ferrando
- Isabel Puig Povedano
- Carla Oliver Garcia
- Maria Martinez Iniesta
Cancer
Oncobell
Scientific production
12
PAPERS
Average IF: 9,919
3
LED PAPERS
Average IF: 9,625
5 PUBLICATIONS IN FIRST DECILE
8 PUBLICATIONS IN FIRST QUARTILE
11 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Devis Jauregui L, Vidal A, Plata Pena L, Santacana M, Garcia Mulero S, Bonifaci N, Noguera Delgado E, Ruiz N, Gil M, Dorca E, Llobet FJ, Coll Iglesias L, Gassner K, Martinez Iniesta M, Rodriguez Barrueco R, Barahona M, Marti L, Vinals F, Ponce J, Sanz Pamplona R, Piulats JM, Vivancos A, Matias Guiu X, Villanueva A, Llobet Navas D. Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer. Adv. Sci. 2022;10(1):doi:10.1002/advs.202204211.
- Oliveira PD, Ribeiro GS, Anjos RO, Dias MA, Farre L, Araújo I, Bittencourt AL. The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) in the prognosis. Plos Neglect. Trop. Dis. 2022;16(10):10807-10807. doi:10.1371/journal.pntd.0010807.
- Garcia Vicién G, Mezheyeuski A, Micke P, Ruiz N, Ruffinelli JC, Mils K, Bañuls M, Molina N, Losa F, Lladó L, Molleví DG. Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern. Cancers. 2022;14(3):doi:10.3390/cancers14030689.
- Herpers B, Eppink B, James MI, Cortina C, Cañellas Socias A, Boj SF, Hernando Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink Clements C, Zondag van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat. Cancer. 2022;3(4):418-436. doi:10.1038/s43018-022-00359-0.
- Solé L, Lobo Jarne T, Álvarez Villanueva D, Alonso Marañón J, Guillén Y, Guix M, Sangrador I, Rozalén C, Vert A, Barbachano A, Lop J, Salido M, Bellosillo B, García Romero R, Garrido M, González J, Martínez Iniesta M, López Arribillaga E, Salazar R, Montagut C, Torres F, Iglesias M, Celià Terrassa T, Muñoz A, Villanueva A, Bigas A, Espinosa L. p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nat. Commun. 2022;13(1):2866-2866. doi:10.1038/s41467-022-30382-9.
Research highlights
PROJECTS
3 Granted competitive projects
10 Ongoing competitive projects
PUBLISHED WORKS
1 Clinical guideline
1 Thesis
INNOVATION
1 License
1 Spin off
NETWORKS
LMRN
Selected projects
- AEC21010. Mechanisms of innate and acquire resistance to immune checkpoint inhibitors in orthoxenografts/PDOX and immunorthoxenografts/immunoPDOX from lung (NSCLC) and bladder cancer. Budget: 299963,75. 2021- . PI: Villanueva Garatachea, Alberto.
- FIS21070. EVALUACIÓN ESPACIAL DEL IMPACTO DEL TRATAMIENTO NEOADYUVANTE SOBRE EL MICROAMBIENTE TUMORAL EN LAS METÁSTASIS HEPÁTICAS DE CÁNCER COLORECTAL. Instituto de Salud Carlos III (ISCIII). Budget: 295409,4. 2022-2024. PI: García Molleví, David.
- FIS22049. Identificación de vulnerabilidades terapéuticas en cáncer de ovario y pulmón analizando las vías de reparación del ADN por Excisión de Nucleótidos (NER) y Recombinación Homóloga (HR). Instituto de Salud Carlos III (ISCIII). Budget: 214170. 2023-2025. PI: Villanueva Garatachea, Alberto.
- FIS21065. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. Instituto de Salud Carlos III (ISCIII). Budget: 135520. 2022-2024. PI: Farre Vallve, Maria Lourdes.
- 18CEE005. EDIReX:EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts. COMISSIÓ EUROPEA. Budget: 121146,25. 2018-2022. PI: Villanueva Garatachea, Alberto.